Bill Ackman’s Three Worst Investments of All Time [LIST]

This is a syndicated repost courtesy of Money Morning - We Make Investing Profitable. To view original, click here. Reposted with permission.

Share!Tweet about this on TwitterShare on FacebookShare on LinkedInEmail this to someonePrint this page

Money manager Bill Ackman‘s hedge fund Pershing Square once boasted extraordinary returns. For instance, in 2014, the fund beat out the S&P 500 by a whopping 27%, with 40% gains.

However, Pershing Square’s returns are not what they use to be…

Last year, the fund posted a negative return of 13.5%; in 2015, it returned negative 20.5%, significantly underperforming markets two years in a row. In fact, since the end of 2012, Pershing has returned 5.7% to investors, while the S&P 500 has skyrocketed 67.4%.

Majorly contributing to Pershing’s recent sagging returns is that three of Ackman’s worst trades ever all happened over the past two years…

Bill Ackman’s Biggest Blunder No. 3: Target Corp. (NYSE: TGT)

In 2007, Ackman set up Pershing Square IV, a single-stock fund that invested $2 billion in Target Corp. (NYSE: TGT) call options and other derivatives that year. The fund ended up losing 90% of that money after TGT shares plummeted 50% in 2009. At the time, Target’s “expect more, pay less” slogan became half irrelevant as consumers began to shy away from the retailer in favor of Wal-Mart, which was cheaper and offered a wider food selection.

In May 2009, Ackman said that Target’s board was too “cozy” and “insular,” and it lacked members with requisite retailing, credit card, and real estate backgrounds. In a letter to shareholders, Ackman said Target “has substantially underperformed its potential” due to the board.

Don’t Miss: Secret testing in New Mexico ghost town set to unleash $127 billion in new wealth. Read more…

Ackman, who owned a 3% stake (24.8 million shares), fought to get on the board along with four other handpicked members. After months of public accusations on both sides, shareholders voted for board appointments on June 3, 2009. All incumbent directors were re-elected with at least 70% of the vote…

In other words, Ackman’s months-long campaign to take over fell flat as he and his hand-selected crew failed to make it on the board. Following the defeat, Ackman sold out of Target at an enormous loss. Shares traded at $70.14 before he first reported his stake; they closed at $51.52 when he announced he had sold his last share.

Bill Ackman’s Biggest Blunder No. 2: Herbalife Ltd. (NYSE: HLF)

Who Is Bill Ackman?

Bill Ackman: Fifty-year-old Ackman’s career began in 1992 when he and fellow Harvard graduate David P. Berkowtiz founded the investment firm Gotham Partners. The firm’s high-profile bid for Rockefeller Center in New York caused investors to flock to the firm, growing it to $500 million in assets. Then in 2004, with $54 million in personal funding, Ackman started Pershing Square Capital Management. Through Pershing, Ackman bought significant shares in companies like Wendy’s Co. (Nasdaq: WEN), Target Corp. (NYSE: TGT), Chipotle Mexican Grill Inc. (NYSE: CMG), and Valeant Pharmaceuticals International Inc. (NYSE: VRX). Today, Ackman is worth $1.4 billion and is No. 256 on the Forbes 400.

Since May 2012, Ackman has maintained that Herbalife Ltd.’s (NYSE: HLF) business structure resembles a pyramid scheme and the company is destined for a major collapse. Later that year, on Dec. 19, news broke on CNBC that Ackman had taken a massive $1 billion short position against Herbalife.

Two years later, it looked as though Ackman’s bet was going to pay off…

In 2014, the Federal Trade Commission (FTC) opened a probe into Herbalife’s business model on Ackman’s allegations the company operated like a pyramid scheme.

Must Read: What is a Ponzi scheme? Click here for our infographic…

But after two years of investigations, the FTC did not find that Herbalife was acting as a pyramid scheme. The determination sent HLF shares up sharply by 18% on July 15, 2016 — the day of the FTC announcement.

Fortune estimated on Jan. 30, 2017, that Ackman may have shorted more than 20 million shares of Herbalife stock. Its calculations suggest Ackman may have lost about $500 million on his short bet.

However, $500 million lost on a short gone wrong will look like chump change compared to Ackman’s next bet, which may go down as one of the worst in Wall Street history…

Bill Ackman’s Biggest Blunder No. 1: Valeant Pharmaceuticals International Inc. (NYSE: VRX)

On April 22, 2014, Bill Ackman and then CEO of Valeant Pharmaceuticals International Inc.’s (NYSE: VRX) Michael Pearson held an event in Manhattan to announce Valeant’s interest in buying Allergan. On stage, Ackman disclosed that he would use his near 10% stake – $3 billion – in Allergan and pledge those shares in favor of an acquisition with Valeant.

Ackman seemed in awe of Pearson’s public speaking, leadership, and thriftiness. During the appearance, Ackman pointed out admiringly that Pearson wouldn’t allow Valeant shareholders to be on the hook for the cost of the auditorium they were using to announce the deal. Ackman had to pick up the bill himself.

The bid ultimately failed, but the relationship between Ackman and Pearson persisted. In fact, Ackman was so confident in Valeant, and in Pearson’s ability to lead it, he forked over $3.2 billion in 2015. He even compared the company to Warren Buffett’s Berkshire Hathaway, declaring, “Valeant is very early stage Berkshire” on May 4, 2014.

Faith in Pearson proved misplaced. The former Valeant CEO had been illegally price-gouging. For example, on Feb. 10, 2015, Valeant bought two lifesaving heart drugs called Nitropress and Isuprel. On the same day as the deal closed, the company hiked the drugs’ prices 525% and 212%, respectively.

The company was also falsifying its accounting. News broke in February 2016 that Valeant had overstated $58 million in sales so it could look more appealing to investors. This caused the company to go $30.66 billion in debt and sell of billions of dollars it had in non-core assets to stay afloat.

Following these revelations, Pearson lost his job on March 8, 2016; Ackman lost $1 billion from his 30.7 million share investment into the debauched pharmaceutical company.

That alone makes Valeant the single worst-ever investment on Ackman’s track record… but the bleeding doesn’t stop there…

Just on Monday (March 13), Ackman gave in and sold his entire stake in Valeant — all 27 million shares — for a $4 billion loss.

 

To get full access to all Money Morning content, click here

About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

Disclaimer: © 2017 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.

 

The post Bill Ackman’s Three Worst Investments of All Time [LIST] appeared first on Money Morning – We Make Investing Profitable.

Wall Street Examiner Disclaimer: The Wall Street Examiner reposts third party content with the permission of the publisher. I curate these posts on the basis of whether they represent an interesting and logical point of view, that may or may not agree with my own views. Some of the content includes the original publisher's promotional messages. In some cases promotional consideration is paid on a contingent basis, when paid subscriptions result. The opinions expressed in these reposts are not those of the Wall Street Examiner or Lee Adler and no endorsement of the content so provided is either expressed or implied by our posting the content. The Wall Street Examiner makes no endorsement or recommendation regarding them. Do your own due diligence when considering the offerings of third party providers.

0 comments